<DOC>
	<DOCNO>NCT03008070</DOCNO>
	<brief_summary>Non-alcoholic steatohepatitis , abbreviate NASH , chronic liver disease may progress cirrhosis . The disease mostly associate obesity type 2 diabetes mellitus , insulin resistance common . However , Treatment NASH significant unmet clinical need . IVA337 next generation pan-PPAR ( peroxisome proliferator-activated receptor ) agonist address pathophysiology NASH : metabolic , inflammatory fibrotic . The purpose research evaluate efficacy safety two dos IVA337 ( 800mg , 1200 mg ) per day 24 week versus placebo adult NASH patient liver steatosis moderate severe necroinflammation without cirrhosis .</brief_summary>
	<brief_title>Phase 2b Study NASH Assess IVA337</brief_title>
	<detailed_description>Randomized ( stratified diabetes ) , placebo-controlled , double-blind , parallel-assignment , dose-range multicenter study There 3 parallel treatment group : placebo , IVA337 800mg day ( Quaque Die , QD ) IVA337 1200mg QD ( identical capsule 400mg IVA337 placebo ) . Both , patient investigator blind . For patient , study duration overall 6 8 month ( 10-day 4-week selection period , 24-week treatment period 4-week follow-up period ) .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult subject , age ≥18 year . NASH histological diagnosis accord currently accept definition EASL AASLD , require combine presence steatosis ( degree ≥ 5 % ) + lobular inflammation degree + liver cell ballooning amount , liver biopsy perform ≤ 6 month screen study confirm central reading screen period SAF Activity score 3 4 ( &gt; 2 ) SAF Steatosis score ≥ 1 SAF Fibrosis score &lt; 4 Subject agrees liver biopsy perform 24 week treatment . Compensated liver disease No cause chronic liver disease ( autoimmune , primary biliary cholangitis , Hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , Wilson 's , α1antitrypsin deficiency , hemochromatosis , etc… ) . If applicable , stable type 2 diabetes , define HbA1c &lt; 8.5 % fast glycemia &lt; 10 mmol/L , change medication previous 6 month , new symptom associate decompensated diabetes previous 3 month . Have stable weight since liver biopsy perform defined 5 % loss initial body weight . Negative pregnancy test postmenopausal . Women childbearing potential ( i.e . fertile , follow menarche become postmenopausal unless permanently sterile ) must use highly effective method contraception ( i.e . combine ( estrogen progestogen contain ) hormonal/ progestogenonly hormonal contraception associate inhibition ovulation , intrauterine device , intrauterine hormonereleasing system , bilateral tubal occlusion , vasectomise partner , sexual abstinence ) Subjects must willing give write informed consent . Evidence another form liver disease . History sustain excess alcohol ingestion : daily alcohol consumption &gt; 30 g/day ( 3 drink per day ) males &gt; 20 g/day ( 2 drink per day ) female . Unstable metabolic condition : Weight change &gt; 5kg last three month , diabetes poor glycemic control ( HbA1c &gt; 8.5 % ) , introduction antidiabetic antiobesity drug/malabsorptive restrictive bariatric ( weight loss ) surgery past 6 month prior screen . History gastrointestinal malabsorptive bariatric surgery within less 5 year ingestion drug know produce hepatic steatosis include corticosteroid , highdose estrogen , methotrexate , tetracycline amiodarone previous 6 month . Significant systemic major illness liver disease , include congestive heart failure ( class C D American Heart Association , AHA ) , unstable coronary artery disease , cerebrovascular disease , pulmonary disease , renal failure , organ transplantation , serious psychiatric disease , malignancy , opinion investigator , would preclude treatment IVA337 and/or adequate follow . HB antigen &gt; 0 , HCV Polymerase chain reaction ( PCR ) test &gt; 0 ( patient history HCV infection include HCV PCR negative since 3 year ) , HIV infection . Pregnancy/lactation inability adhere adequate contraception woman childbearing potential . Active malignancy except cutaneous basocellular carcinoma . Any condition , opinion investigator would impede competence compliance possibly hinder completion study . Body mass index ( BMI ) &gt; 45 kg/m2 . Type 1 diabetes . Diabetic ketoacidosis Fasting Triglycerides &gt; 300 mg/dL . Hemostasis disorder current treatment anticoagulant . Contraindication liver biopsy . History , , current cardiac dysrhythmias and/or history cardiovascular disease event , include myocardial infarction , except patient well control hypertension . Participation clinical study within previous 3 month . Have know hypersensitivity ingredient excipients Investigational medicinal product ( IMP ) Be possibly dependent Investigator sponsor ( e.g. , include , limited , affiliated employee ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-Alcoholic Steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>peroxisome proliferator-activated receptor ( PPAR )</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Fatty Liver</keyword>
	<keyword>Non-alcoholic Fatty Liver Disease</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>IVA337</keyword>
</DOC>